Project Grant HT94252410089
Award Date
4/1/24
Completion Date
3/31/26
Dollars Obligated
$188K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19111, USA
Similar Awards
The federal Project Grant award for "TARGETING P2X7 RECEPTOR IN RENAL CELL CARCINOMA", totaling $1,269,000.00, was awarded to The Institute For Cancer Research, a non-profit subsidiary of Temple University, by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports biomedical research focused on developing new treatments for kidney cancer, a key health concern for military service members and veterans. The Institute For...
The U.S. Defense Health Agency awarded a $1,880,000 Project Grant to The Institute for Cancer Research, a non-profit subsidiary of Temple University, under the Military Medical Research and Development program (CFDA 12.420). The funding will support a 3-year research project to study the SRPK1-AKT signaling axis in endometrial cancer. As a prime grantee, The Institute for Cancer Research will conduct preclinical testing and analysis to develop new approaches for cancer prevention and...
The federal Project Grant award, valued at $1,944,610.00 and effective from April 1, 2025 to March 31, 2028, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The primary awardee, Sloan-Kettering Institute for Cancer Research, will conduct research to understand tumorigenesis and identify therapeutic targets in CDK12-mutant prostate cancer. This work will involve collaboration with The University of Texas MD Anderson Cancer...
The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...
The Department of the Army Medical Command awarded a $564,000 Project Grant to The Institute For Cancer Research through the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research exploring the role of the MUL1 gene in the development of prostate cancer. The Institute For Cancer Research, a non-profit subsidiary of Temple University, will conduct this 2-year research project from May 1, 2025, to April 30, 2027. The grant funding will enable the...
The U.S. Defense Health Agency awarded a $700,788 Project Grant to The Institute For Cancer Research, a non-profit subsidiary of Temple University, under the Military Medical Research and Development program (CFDA 12.420). The funding supports a 3-year research project to study the targeting of the nuclear necroptosis pathway in the pancreatic cancer microenvironment. As a prime grantee, The Institute For Cancer Research will conduct preclinical testing, biomarker analysis, and other specialized...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,128,000 Project Grant to The Institute For Cancer Research to conduct research on "Restoring PALB2 Function as a Mechanism of PARP1 Resistance in BRCA1-Mutant EOC". The award, with a performance period from July 1, 2024 to June 30, 2028, supports innovative scientific research aimed at improving health outcomes for military service members, veterans, and the broader...
The U.S. Department of Defense's Defense Health Agency awarded a $752,000 Project Grant to The Institute For Cancer Research, a subsidiary of Temple University, to investigate therapeutic response disparities in locally advanced rectal cancer. This grant, funded under the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform health care for service members and the public through innovative and impactful research....
The federal Project Grant award of $312,610.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The purpose of the award is to support research on the "ROLE OF FUNCTIONAL FACTORS IN AR REPROGRAMMING AND PROGRESSION OF PROSTATE CANCER". The award was made to Weill Medical College of Cornell University, a prominent academic medical institution, on September 30, 2024, with a performance period ending on September 29,...
The Institute For Cancer Research, a non-profit research organization and subsidiary of Temple University, was awarded a $534,445 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to investigate NETRIN G1 ligand as a new immunomodulatory target and early biomarker in pancreatic cancer, with a project period from August 1, 2023 to July 31, 2026. The Institute For Cancer Research has extensive...